Production of monoclonal antibodies that recognize specific and cross-reactive antigens of Fusobacterium nucleatum by Bird, P. S. & Seymour, G. J.
INFECTION AND IMMUNITY, Mar. 1987, p. 771-777
0019-9567/87/030771-07$02.00/0
Copyright C 1987, American Society for Microbiology
Production of Monoclonal Antibodies That Recognize Specific and
Cross-Reactive Antigens of Fusobacterium nucleatum
PHILIP S. BIRD* AND GREGORY J. SEYMOUR
Department of Social and Preventive Dentistry, University of Queensland Dental School, Brisbane 4000,
Queensland, Australia
Received 18 September 1986/Accepted 8 December 1986
Monoclonal antibodies (MAbs) against the cell sulrface antigens of Fusobacterium nucleatum 263 were
obtained by fusion of murine myeloma cells (P3-NSI/1-Ag4-1) with the splenocytes of BALB/c mice immunized
with whole cells of F. nucleatum 263. Screening was performed using an enzyme-linked immunosorbent assay
(ELISA) against the immunizing strain, F. nucleatum 263. Further selection was done using a bacterial panel
consisting of Bacteroides, Actinomyces, Streptococcus, Fusobacterium, and Escherichia species. Twelve MAbs
were selected on the basis of this screening procedure, seven of which reacted specifically with F. nucleatum
263. Two reacted with F. rnucleatum 263 and ATCC 25586, and three reacted with F. nucleatum 263, ATCC
25586, and UQD-003 (a clinical isolate) and also cross-reacted with Fusobacterium russii ATCC 25533. The
selected MAbs were then further characterized by absorption experiments with suspensions of intact whole
bacterial cells, and the residual binding activity of the supernatants was determined in an ELISA. To determine
whether the MAbs reacted with the same or different epitopes, pairs of MAbs were reacted together and
independently in a checkerboard manner in an ELISA. The additive or nonadditive nature of the reactivity was
determined. A competitive inhibition assay was performied using one labeled and selected unlabeled MAbs. The
results of these experiments suggested some epitope sharing among the selected MAbs that reacted with a
specific antigen on F. nucleatum and also shared cross-reactive antigens with the three strains of F. nucleatum
and F. russii.
Specific bacterial species play a major role in the etiology
of periodontal disease (10). Fusobacterium nucleatum, a
gram-negative anaerobic bacterium, has frequently been
isolated from the subgingival sites of advancing lesions in
patients with chronic inflammatory periodontal disease (25,
28, 30). Furthermore, studies have shown the presence of
serum immunoglobulin G (IgG) antibodies specific for F.
nucleatum which were significantly raised in periodontally
diseased patients when compared with healthy individuals
(4, 22, 23). These findings indicate a close association of F.
nucleatum with chronic inflarnmatory periodontal disease.
Periodontal disease has been shown to have an immuno-
logical basis (16, 26), and therefore the mechanisms which
control the immune response need to be studied, in particu-
lar the response to the bacterial cellular antigens and their
products. Recently, studies have focused on the immune
responsiveness to F. nucleatum in hunan and animal mod-
els. Workers have shown that extracts from F. nucleatum
have a suppressive effect on humian peripheral blood lym-
phocytes in vitro (27) and are able to induce polyclonal
B-lymphocyte activation in vitro (19). Yoshie et al. (34)
demonstrated that in mice an extract of F. nucleatum had an
adjuvant effect on humoral immunity, as indicated by an
increase in plaque-forming cells, a suppressive effect on
cell-mediated immunity, a reduction in cytotoxic T cells to
an allograft transplant, and an enhancing effect on phago-
cytic functions, with increased carbon clearance rates and
bacteriocidal and acid phosphatase activities. Enhancement
of B-cell function and suppression of T cells were further
demonstrated with mucosal presentation of intact F.
nucleatum cells (13).
Studies of these immune responses may be made easier by
using monoclonal antibodies (MAbs), which can be used to
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purify the target antigen(s) responsible for eliciting the
response described above. In addition, it may be possible to
study the control of B-cell responses to bacterial antigens via
idiotypic networks (12). The purpose of this paper is to
describe the production and characterization of MAbs that
react with F. nucleatum. Twelve MAbs which reacted with
specific and cross-reactive antigens of F. nucleatum are
described.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains used were as fol-
lows: F. nucleatum 263, Actinomyces viscosus T-14, and
Streptococcus sanguis 36A (kindly donated by A. C. R.
Tanner, Forsyth Dental School, Boston, Mass.); F.
nucleatum ATCC 25586, Fusobacterium necrophorum
ATCC 25286, Bacteroides gingivalis ATCC 33277, Bacte-
roides intermedius ATCC 25611, and Fusobacterium russii
ATCC 25533 (kindly donated by D. Love, Department of
Veterinary Pathology, University of Sydney, N.S.W., Aus-
tralia); Fusobacterium mortiferum ATCC 25551 and Esche-
richia coli ATCC 25922 (obtained from BactiDisks, Medical
Diagnostics, Springwood, Queensland, Australia); Fusobac-
terium varium NCTC 10560 (kindly donated by the State
Health Department of Western Australia, Perth); and F.
nucleatum UQD-003, which was isolated from a clinical
source (Department of Social and Preventive Dentistry;
University of Queensland Dental School, Brisbane,
Queensland, Australia).
Media and cultivation. Stock cultures were maintained in
liquid nitrogen in Trypticase soy broth (BBL Microbiology
Systems, Cockeysville, Md.) containing 10% glycerol. Bac-
teria were checked for purity by growth on CDC blood agar
prepared from a Trypticase soy agar base (40 g/liter; BBL)
supplemented with agar (5 g/liter), yeast extract (5 g/liter;
GIBCO Diagnostics, Madison, Wis.), L-cysteine hydrochlo-
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ride (0.5 g/liter; BDH, Poole, England), menadione (1 jig/ml;
Sigma Chemical Co., St. Louis, Mo.), hemin, bovine type (5
,ug/ml; GIBCO), and 5% defibrinated laked horse blood (31).
Cultures were incubated at 37°C in an atmosphere of 80%
N2, 10% C02, and 10% H2 in anaerobic jars (BBL) for 3 to 5
days.
Bacteria were grown in brain heart infusion broth (37.0
g/liter; Difco Laboratories, Detroit, Mich.) supplemented
with yeast extract (5 g/liter; GIBCO), hemin (5 jig/liter;
Sigma), menadione (1 ,ug/ml; Sigma), L-cysteine hydrochlo-
ride (0.5 g/liter; BDH), sodium formate (2 g/liter), sodium
fumerate (3 g/liter), resazurin (1 g/liter; Sigma), and DL-
dithiothreitol (0.1 g/liter; Sigma). The broth was prepared,
prereduced, and anaerobically sterilized as described by
Holdeman et al. (11) by using the VPI Anaerobic Culture
System (Bellco Glass, Inc., Vineland, N.J.). The bacteria
were harvested by centrifugation (model TJ-6; Beckman
Instruments, Inc., Fullerton, Calif.) at 1,730 x g for 30 min
and washed twice in sterile Dulbecco phosphate-buffered
saline (PBS) containing 10 mM EDTA, and the suspensions
were stored at -20°C as 1-ml aliquots.
Immunization of mice. BALB/c mice (6- to 8-week-old
females) were obtained from the University of Queensland
Central Animal Breeding House. The mice were immunized
intraperitoneally with 0.1 ml (109 CFU/ml) of a bacterial
suspension of F. nucleatum 263 on days 0 and 14. The mice
were tail bled on day 21, and antibody levels to F. nucleatum
263 were determined by an enzyme-linked immunosorbent
assay (ELISA) (see below). Mice with the highest titer were
selected and boosted on day 28 with 0.2 ml (109 CFU/ml) of
a bacterial suspension split into two equal doses, one given
intraperitoneally and the other given as an intracardial
injection 4 to 5 h later.
Production of hybridomas. The technique used for the
production of hybridomas was essentially that of Kohler and
Milstein (15) with the modifications of Galfre et al. (9). The
normal culture medium consisted of RPMI 1640 (Flow
Laboratories, Sydney, Australia) supplemented with 10%
heat-inactivated fetal bovine serum (Symbio Products,
Brisbane, Australia), 2 mM L-glutamine (Flow), penicillin
(50 IU/ml; Flow), and streptomycin (50 ,ug/ml; Flow). The
nonsecreting mouse myeloma line P3-NSI/1-Ag4-1 (NSI)
(17) was grown initially in RPMI 1640 containing 6-
thioguanine (40 ,ug/ml; Sigma) to prevent revertants. NSI
cells were then fused with immune mouse spleen cells at an
NSI/spleen cell ratio of 1:5 in the presence of 50% (wt/vol)
polyethylene glycol (1450D; Sigma). This was then diluted
with serum-free RPMI 1640 at 37°C and centrifuged at 150 x
g for 7 min. The cells were suspended (2 x 105 cells per ml)
in RPMI 1640 containing hypoxanthine (13.6 ,ug/ml), ami-
nopterin (0.176 ,ug/ml), thymidine (3.88 ,ug/ml; Sigma), 20%
fetal bovine serum, and P-mercaptoethanol (5 x 10-5 mM)(HAT medium) (14). After fusion, the cells were plated out
into 24-well cluster plates (flat bottom; Linbro; Flow) by
adding 1 ml of cell suspension per well and were placed in a
humidified incubator (5% CO2 in air) at 37°C. After 7 days, 1
ml of HAT medium was added. Culture supernatants were
monitored, and when a change to acid conditions was
observed, 1 ml of medium was removed and replaced by 1 ml
of fresh HAT medium. Screening procedures were per-
formed after 10 days by an ELISA (see below). Hybridomas
secreting antibodies with a specific reactivity to F.
nucleatum were cloned at least twice by the limiting dilution
method (35). The cloned cells were expanded and injected
into pristane-primed mice (0.5 ml of 2,6,10,14-tetramethyl-
pentadecane [Aldrich Chemical Co., Inc., Milwaukee,
Wis.]). Culture supernatants and ascites were stored at
-20°C, and cells were frozen in the presence of 4% dimethyl
sulfoxide in fetal bovine serum and stored in liquid nitrogen.
Detection of MAbs directed against F. nucleatum 263. (i)
Preparation of bacterium-coated microtrays. Bacterium-
coated 96-well plates were prepared by using the method of
Nachamkin et al. (21). Briefly, a suspension of washed
bacteria in PBS at an optical density of 0.50 (model 100-60
spectrophotometer; Hitachi, Tokyo, Japan) at 750 nm was
added to the wells of a 96-well plate (50 ,u per well; flat
bottom DP2; Disposable Products, Adelaide, South Austra-
lia, Australia). The plates were centrifuged at 1,500 x g for
5 min at 4°C; 100 ,ul of cold 0.25% glutaraldehyde in PBS was
then carefully added to each well, and the plates were
centrifuged for an additional 5 min. After 15 min at room
temperature (RT) the PBS-glutaraldehyde was flicked out,
and the wells were washed three times with PBS-0.5%
(vol/vol) Tween 20 (PBS-T). Finally, the wells were filled
with PBS-T containing 1.0% bovine serum albumin (CSL,
Melbourne, Australia) and incubated for 2 h at RT to block
nonspecific binding sites. The plates were then stored for up
to 1 month at 4°C without loss of activity.
(ii) ELISA. The ELISA was performed by the method of
Engvall and Perlmann (5) with the plates precoated with
bacteria or antiserum at the appropriate dilution. The pri-
mary antibody (100 ,u) was added to the wells, incubated for
60 min at RT or overnight at 4°C, and washed three times
with PBS-T, and the excess moisture was tapped out; 100 ,u
of rabbit anti-mouse immunoglobulin conjugated to horse-
radish peroxidase (1:1,000) (RAM-HRPO; Dakoplasts) in
PBS-T containing 0.1% bovine serum albumin was then
added to all wells and incubated for 60 min at RT. The plates
were washed four times with PBS-T and developed by the
addition of 150 ,ul of activated substrate to each well. The
substrate was activated immediately before use and was
prepared by adding 10 ,ul of a 3% H202 solution to 10 ml of
solution containing 1 ml of 2.5 mM o-toluidine (Eastman
Kodak Co., Rochester, N.Y.) diluted in 9 ml of 100 mM
citrate buffer (pH 4.5) with 0.025 mM EDTA. The reaction
was stopped after 10 min by the addition of 3 M hydrochloric
acid (50 RI per well). The A450 was recorded with a Titertek
Uniscan (Flow).
(iii) Isotype and subclass determination. Rabbit anti-mouse
immunoglobulin subclass-specific antisera (Miles Scientific,
Div. Miles Laboratories, Inc., Melbourne, Australia) at a
1:2,000 dilution in 0.05 M carbonate buffer (pH 9.6) were
used to coat 96-well plates (Immunoplate IIF 442404; Nunc,
Roskilde, Denmark). This coating dilution of antiserum was
determined by block titration against horseradish peroxi-
dase-conjugated anti-mouse antibody with normal BALB/c
mouse serum as the primary antibody. An optimnum level of
coating was taken as an A450 of 1.00. Antibody subtyping was
performed in an ELISA (described above).
Absorption experiments. (i) Absorption of MAb with intact
F. nucleatum 263 cells. A suspension of washed intact F.
nucleatum 263 cells at an A750 of 2.15 was diluted twofold in
PBS, and then 40 pI of each dilution of bacteria (neat to 1:32)
was added to the wells of a 96-well V-bottom plate (Dispos-
able Products). MAb (120 RI) at a standard dilution was
added to all bacterial suspensions. This standard dilution had
been adjusted so that it gave an A450 of 1.00 when reacted in
an ELISA with F. nucleatum 263-coated plates. Wells
containing diluted MAb only were included as nonabsorbed
controls. Plates were incubated for 2 h at RT with occasional
agitation and then overnight at 4°C.
The bacteria were pelleted in the microplates by centrifu-
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gation at 1,750 x g for 20 min at 4°C, and 100 ,ul of
supernatant was carefully removed from each well and
transferred to wells coated with F. nucleatum 263. Readings
from triplicate wells were averaged and then calculated as a
percentage of the reactivity of an unabsorbed MAb to F.
nucleatum 263, which was taken as 100% binding activity.
The residual binding activity was assessed by an ELISA of
the absorptions performed in triplicate.
(ii) Absorption of MAb with sonicated F. nucleatum 263
cells. A washed suspension of F. nucleatum 263 cells was
prepared as in section i above. The bacterial suspension (1
ml) was mixed with 100 ,ul of 20% sodium dodecyl sulfate
(Bio-Rad Laboratories, Richmond, Calf.) and 10 ,u of P-
mercaptoethanol (Sigma), placed in a sonicated water bath
(model B12; Branson Sonic Power Co., Danbury, Conn.)
until the suspension was visually clear, and then centrifuged
for 5 min at 9,000 x g (Beckman Microfuge-B). The protein
concentration was equal to 8.0 mg/ml, as determined by the
method of Lowry et al. (18). A 10-fold dilution series (10-' to
10-5) of the sonic extract was prepared, and 40 RI of the
diluted sonic extract was mixed with 120 ,ul of diluted MAb
(as in section i above) in small serofuge tubes and incubated
for 2 h at RT and then overnight at 4°C. The mixture was
centrifuged at 9,000 x g (Beckman Microfuge-B) for 5 min,
and then the supernatant was treated as described in i above.
Additive binding assay. The method used for the assay of
additive binding was described by Friguet et al. (8). Each
MAb was titrated in an indirect ELISA against glutaralde-
hyde-fixed F. nucleatum 263 cells to determine the satura-
tion binding level. Then the antibodies were mixed together
in a 1:1 ratio in a checkerboard manner, and 100 ,ul of this
mixture was added to F. nucleatum-coated 96-well plates.
The reactivity was determined by an ELISA after overnight
incubation at 4°C.
The additive or nonadditive nature of the binding of the
MAbs to F. nucleatum 263 was expressed as a percentage
calculated by the formula derived by Friguet et al. (8):
additive binding = {[2Al+2/(Al + A2)] -1} x 100, where Al+2
is the saturation binding of the mixture of MAbs, and Al and
A2 are the individual saturation binding levels for each
antibody.
Preparation of peroxidase-labeled MAb by using a two-step
glutaraldehyde method. MAb 4BA4 was labeled with horse-
radish peroxidase (Sigma P3875, type VI; 300 U/mg of
protein) by the method of Avrameas et al. (1) as described by
Voller et al. (33). Briefly, 10 mg of peroxidase in 0.2 ml of 0.1
M phosphate buffer (pH 6.8) containing 1.25% glutaralde-
hyde was allowed to stand overnight at RT. The glutaralde-
hyde was removed by passage through a Sephadex G-25
column (PD-10 column; Pharmacia, Uppsala, Sweden)
which had been equilibrated with normal saline. The eluate
was concentrated to 1 ml by vacuum dialysis (Visking
dialysis tubing; molecular weight cutoff, 12,000 to 14,000;
Union Carbide Corp.) and added to an equal volume of
normal saline containing 5 mg of antibody per ml. The
antibody had been prepared from ascitic fluid by precipita-
tion with 45% ammonium sulfate (35), and the antibody
concentration was determined by A280. Sodium carbonate-
bicarbonate buffer (1 M; pH 9.5; 100 Rd) was added to the
antibody solution and allowed to stand for 24 h at 4°C, and
then 200 ,ul of 0.1 M lysine monohydrochloride (BDH) was
added and, after standing for 2 h at RT, extensively dialyzed
against PBS at 4°C. The conjugate was made to 50% con-
centration with glycerol (pH 7.2) containing 1.0% bovine
serum albumin and stored at
-20°C as aliquots. The protein/
conjugate ratio of 0.35 was determined by A280 and A490.
Inhibition of binding of peroxidase-labeled MAb 4BA4 to F.
nucleatum 263 by unlabeled MAbs. Unlabeled MAbs (100 ,Il)
at the saturation binding level (described above) were added
to F. nucleatum-coated ELISA 96-well plates, incubated
overnight at 4°C, and then washed three times with PBS-T.
After nonspecific absorption was blocked with PBS-
T-bovine serum albumin, 100 ,ul of peroxidase-labeled MAb
4BA4 (1:1,000) was added to the wells, and the plates were
incubated for 60 min at RT. Inhibition of binding was
determined by an ELISA.
RESULTS
Production of hybridomas. After somatic cell hybridiza-
tion, 156 hybrids were identified from four fusions of im-
mune BALB/c splenocytes with the immune myeloma cells
(NSI), and, of these, 20 hybrids produced MAbs that reacted
specifically in the screening ELISA against the F. nucleatum
263 immunizing strain. A positive control (serum from a
BALB/c mouse hyperimmunized against F. nucleatum, di-
luted 1:1,000 in PBS) and a negative control (normal whole
BALB/c mouse serum diluted 1:100) were included in the
screening assays.
Specificity and reactivity of MAbs to F. nucleatum 263. The
positive clones were further tested against a panel of bacteria
(described in Materials and Methods), and it was found that
these 20 MAbs could be further subdivided into four reac-
tivity groups: group 1 (eight MAbs) reacted against all the
bacteria tested (data not shown); group 2 (seven MAbs)
reacted only with the immunizing strain, F. nucleatum 263;
group 3 (two MAbs) reacted with F. nucleatum 263 and
ATCC 25586; and group 4 (three MAbs) reacted against all
F. nucleatum strains (263, ATCC 25586, and UQD-003) and
also cross-reacted with F. russii ATCC 25533. No reactivity
was found against the other bacterial species tested.
The reactivity results were expressed as a graded ELISA
score from 0 to 4 based on optical density at 450 nm as
follows: <0.10 = 0, 0.11 to 0.50 = 1, 0.51 to 1.00 = 2, 1.01
to 2.00 = 3, and >2.00 = 4. The readings were recorded as
averages for triplicate wells corrected by the subtraction of
readings from wells without the primary antibody. The
readings were obtained from a 1:10 dilution of tissue culture
supernatant in PBS, in which the hybrids were grown to
maximal cell density before testing for reactivity. The spec-
ificity and graded reactivity of the MAbs and their isotype
and subclass determination are shown in Table 1.
Characteristics of selected MAbs. Ten MAbs were selected
for further characterization (five MAbs from group 2 and all
MAbs from groups 3 and 4) (Table 1). MAbs 4AB5 and 4BC2
were not selected due to their low specific reactivities of 0.22
and 0.27, respectively, in an ELISA, and in addition the
hybridomas were difficult to grow in culture. The selected
MAbs were cloned by limiting dilution, grown in culture, and
passaged through pristane-treated BALB/c mice to produce
malignant ascites.
MAb 4BD6 could not be produced as an ascitic fluid and
was therefore propagated only in tissue culture. Unfortu-
nately, this hybridoma was eventually lost.
Absorption experiments. (i) Absorption of MAbs with intact
F. nucleatum 263 cells. MAbs 4BA4, 4BB1, 4AA1, and 7CA4
were used as 45% ammonium sulfate preparations. 7DB5,
7DA6, 7AC5, 7AA3, and 6CD2 were used as raw ascitic fluid
(heat inactivated), and 4BD6 was used as a tissue culture
supernatant. The residual binding activity of MAbs 4BA4
and 4BD6 was absorbed out completely by a 1:16 dilution of
intact F. nucleatum 263 cells. MAbs 4BB1 and 4AA1 were
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TABLE 1. Specificity and reactivity of MAbs against a bacterial
panel
ELISA score withc:
Reactivity Subclassgrouptv MAba and F. nucleatum F. russiiisotypeb 263 ATCC 25586 UQD-003 ATCC 25533
2 4BA4 IgG2a(K) 4 0 0 0
4BB1 IgG2a(K) 2 0 0 0
4AA1 IgGl(K) 2 0 0 0
4BD6 IgGl(K) 3 0 0 0
4AB5 IgM(K) 1 0 0 0
7DB5 IgG2b(K) 2 0 0 0
4BC2 IgG2b(K) 1 0 0 0
3 7DA6 IgG2a(K) 1 2 0 0
7AC5 IgGl(K) 1 2 0 0
4 7AA3 IgGl(K) 4 1 4 1
6CD2 IgGl(K) 1 1 1 1
7CA4 IgG1(K) 4 2 4 1
a Tissue culture supernatants (diluted 1:10 in PBS) harvested from cultures
grown to maximal cell densities.
b MAb isotype and subclass determined by ELISA.
c Results are expressed as a graded ELISA score based on optical density
at 450 nm as follows: 0 = <0.10, 1 = 0.11 to 0.50, 2 = 0.51 to 1.00, 3 = 1.01
to 2.00, and 4 = >2.00.
not absorbed out, residual binding levels being 64 and 60%,
respectively, when absorbed with the neat suspension of F.
nucleatum and not greater than 50% at all other dilutions;
subsequent testing has produced the same results. This was
further investigated using a sonicated preparation of F.
nucleatum 263 (see below). MAb 7DB5 was not absorbed
out and had a residual binding activity of 27 and 31% in the
1:8-to-neat range, rising to 50% at a 1:32 dilution. The results
in Fig. la illustrate the residual binding ofMAbs of reactivity
group 2, which are specific for F. nucleatum 263 only.
Residual activity remaining after absorption of MAb
groups 3 and 4 showed similar patterns (Fig. lb). After
absorption, binding activity for MAbs 7AC5 and 6CD2 was
less than 10% over the dilution range, whereas 7CA4 was
absorbed out with the neat suspension (2% activity), with
activity rising gradually to 53% at a 1:32 dilution. MAb 7AA3
had 35% reactivity remaining after absorption with the neat
suspension, which rose to 97% at dilutions of 1:8 to 1:32, and
7DA6 had 45% remaining with the neat suspension, with a
gradual rise to 77% at 1:32.
(ii) Absorption of MAbs 4BB1 and 4AA1 with sonicated F.
nucleatum 263. After absorption with a 1:10 dilution of sonic
extract, the residual binding of 4BB1 was absorbed out
completely, whereas 52% activity remained for 4AA1. When
the concentration of the bacterial sonic extract was de-
creased to 1:100, 80% residual binding activity remained for
both 4BB1 and 4AA1. The activity rose to 91 and 93%,
respectively, with a 1:1,000 dilution of sonic extract and 94
and 96%, respectively, with a 1:100,000 dilution. The results
are shown in Fig. 2.
(iii) Absorption ofMAb by F. nucleatum and F. russii. MAb
tissue culture supernatants were absorbed at their 50%
binding level with F. nucleatum 263, ATCC 25586, and
UQD-003 and F. russii ATCC 25533. The supernatants were
tested for residual antibody activity in an indirect ELISA
against the four bacterial strains coated in 96-well plates and
compared with an unabsorbed control. The results obtained
with MAbs from group 2, which reacted specifically with F.
nucleatum 263 (Table 1), showed that MAbs 4BA4 and 4BD6
reacted with and were absorbed out completely by F.
nucleatum 263. MAbs 4BB1 and 4AA1 reacted with but were
not absorbed out by intact F. nucleatum 263 cells. This
group of MAbs did not react with and were not absorbed out
by F. nucleatum ATCC 25586 or UQD-003 or F. russii
ATCC 25533 (Table 2).
In group 3 (7DA6 and 7AC5), both MAbs reacted with F.
nucleatum 263 and ATCC 25586, but when MAb 7AC5 was
absorbed with intact F. nucleatum 263 cells, this resulted in
a residual binding activity of 82%, whereas the residual
binding activity remaining after absorption with F.
nucleatum ATCC 25586 was 37%. When MAb 7DA6 was
absorbed with F. nucleatum 263 and ATCC 25586, the
binding activity remaining was 92 and 77%, respectively
(Table 2).
In group 4, MAbs 7AA3, 6CD2, and 7AC4 reacted with F.
nucleatum 263, ATCC 25586, and UQD-003 and also with F.
russii ATCC 25533. MAb 7AA3 reacted strongly with F.
nucleatum 263 and UQD-003, moderately with F. nucleatum
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FIG. 1. Residual binding activity of supernatants determined
after absorption with intact F. nucleatum 263 cells. The reactivity
was calculated as a percentage of the reactivity of an unabsorbed
MAb to F. nucleatum 263, which was taken as 100% binding
activity. A twofold dilution series of bacteria was mixed with MAbs
at a dilution adjusted to give an A450 of 1.00 in an ELISA with F.
nucleatum 263-glutaraldehyde-coated plates. Results are shown for
the following MAbs at the indicated dilutions. (a) 0, 4BA4
(1:20,000); A, 4BB1 (1:40); 0, 4AA1 (1:100); *, 4BD6 (1:100); A,
7DB5 (1:80). (b) 0, 6CD2 (1:300); A, 7AA3 (1:5,000); *, 7CA4
(1:2,000); 0, 7DA6 (1:200); A, 7AC5 (1:150).
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FIG. 2. Residual binding activity of supernatants determined
after absorption with sonicated F. nucleatum 263 cells. The reactiv-
ity was calculated as a percentage of the reactivity of an unabsorbed
MAb to F. nucleatum 263, which was taken as 100% binding
activity. The sonic extract (protein concentration, 8 mg/ml) was
diluted in a 10-fold series and mixed with MAbs adjusted to a
dilution that gave an A450 of 1.00 in an ELISA with F. nucleatum-
glutaraldehyde-coated plates. Shown are results for MAb 4AA1 at a
1:40 dilution (0) and MAb 4BB1 at a 1:100 dilution (A).
ATCC 25586, and weakly with F. russii ATCC 25533. In
aborption studies with F. nucleatum strains, the remaining
residual activity of the supernatant was F. nucleatum 263,
13%; F. nucleatum ATCC 25586, 18%; F. nucleatum
UQD-003, 20%; and F. russii, 67%. MAb 6CD2 reacted less
with F. nucleatum ATCC 25586 than with the other three
bacterial strains. Absorption with the bacteria gave residual
levels as follows: F. nucleatum 263, 60%; F. nucleatum
ATCC 25586, 56%; F. nucleatum UQD-003, 52%; and F.
russii, 40%. MAb 7CA4 reacted strongly with F. nucleatum
263 and UQD-003, moderately with F. nucleatum ATCC
TABLE 2. Comparison of MAb reactivity before and after
absorption with each strain of F. nucleatum and F. russii ATCC
25533a
Optical density at 450 nm withc:
F. nucleatum F. russii
MAb Dilution" .rsl
263 A2T5CC UQD-003 A25T5CC
4BA4 1:100 0.22/1.40 0.18/0.16 0.19/0.20 0.16/0.18
4BD6 1:100 0.41/1.00 0.13/0.17 0.20/0.22 0.17/0.17
4BB1 1:10 0.33/0.28 0.16/0.15 0.18/0.19 0.18/0.16
4AA1 1:10 0.34/0.33 0.13/0.16 0.20/0.18 0.16/0.15
7DA6 1:10 0.34/0.37 0.30/0.39 0.15/0.14 0.16/0.18
7AC5 1:10 0.23/0.28 0.16/0.43 0.20/0.19 0.17/0.17
7AA3 1:100 0.24/1.90 0.18/1.00 0.34/1.70 0.18/0.26
6CD2 1:100 0.27/0.44 0.13/0.23 0.22/0.42 0.20/0.49
7CA4 1:100 0.42/1.92 0.16/0.93 0.30/1.86 0.18/0.28
a Supematants were reacted in an ELISA in which plates were coated with
the absorbent bacterial strain.
b Dilution of tissue culture supernatant giving 50% binding to glutaralde-
hyde-bacteria-coated 96-well plates, determined by titration.
I Absorbed MAb/unabsorbed MAb. Readings of triplicate results corrected
for blank readings. Bacterial suspensions were used at an A750 of 0.50.
TABLE 3. Additive binding assay to determine additive or
nonadditive nature of reactivity of MAbs to F. nucleatum
263-coated ELISA plates
Additive binding index (%)b with MAb:
MAba
4BB1 4AA1 4BD6 7DB5 7DA6 7AC5 7AA3 6CD2 7CA4
4BA4 39 55 34 62 50 58 61 71 47
4BB1 27 28 20 20 33 90 94 76
4AA1 4 45 63 25 62 38 48
4BD6 33 27 16 30 4 25
7DB5 45 13 106 48 101
7DA6 31 95 51 81
7AC5 11 13 24
7AA3 76 17
6CD2 72
a MAbs diluted and used at saturated binding levels.
b Additive binding index calculated by formula derived by Friguet et al. (8)
(see the text).
25586, and weakly with F. russii. When 7CA4 was absorbed
with the bacterial strains, the residual levels were as follows:
F. nucleatum 263, 22%; F. nucleatum ATCC 25586, 17%; F.
nucleatum UQD-003, 16%; and F. russii, 64%. The results
are shown in Table 2.
Additive binding assay. The results which indicate whether
the MAbs reacted with the same or different epitopes on F.
nucleatum 263 are shown in Table 3. The absence of
nonspecific binding was determined by the reactivity of the
MAbs at the saturated binding levels against F. mortiferum
ATCC 25551 and B. gingivalis ATCC 33277.
Inhibition of binding of peroxidase-labeled 4BA4 by unla-
beled MAbs. An experiment was performed to determine the
inhibition of binding of peroxidase-labeled MAb 4BA4 by
unlabeled MAbs. The MAbs were used at their saturation
binding capacity. Horseradish peroxidase-conjugated 4BA4
was found to be inhibited by unlabeled 4BA4. No inhibition
of binding of conjugated 4BA4 was observed with the other
unlabeled MAbs.
DISCUSSION
In this paper we describe the production of hybrid cell
lines that produce MAbs directed against antigens of F.
nucleatum 263 and report on the cross-reactivity of these
MAbs with other strains of F. nucleatum (ATCC 25586 and
UQD-003) and another Fusobacterium species, F. russii
ATCC 25533. All other Fusobacterium species and bacterial
genera that were tested, such as Bacteroides, Actinomyces,
Streptococcus, and Escherichia, were negative.
Initial analysis of the reactivity and specificity of these
MAbs used whole bacteria in an indirect ELISA under
conditions of antibody excess. The results were then ex-
tended in absorption studies with suspensions of whole
bacteria, and when low levels of absorption were detected,
sonicated bacteria were used. In the latter method of testing,
the MAbs were used in a quantitative absorption assay for
the expression and recognition of antigens under conditions
of antigen excess. With these approaches, the differences in
reactivity were a reflection not only of the number of
antibody molecules present but also of the affinity and
avidity of the antibody, the epitope density, and the acces-
sibility of the target antigen.
The reactivity of one group of MAbs (group 2) was with a
strain-specific antigen (or antigens) which was only detected
on F. nucleatum 263. MAbs in group 3 reacted with an
antigen that was shared by both F. nucleatum strains, 263
and ATCC 25586.
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A group-specific antigen was detected on the three F.
nucleatum strains (263, ATCC 25586, and UQD-003) by
another group of MAbs (group 4), and this antigen (or
antigens) was also detected on another Fusobacterium spe-
cies, F. russii ATCC 25533. All the bacteria used in this
study were grown under the same cultural conditions, and
therefore the presence of antigenic determinants on these
bacteria related only to species or strain differences.
It has been shown that there are different electrophoretic
protein patterns among different strains of F. nucleatum
(20); morphological and physiological differences also exist
among the strains (30). In a recent study it was found that
there was genetic heterogeneity among 58 strains isolated
(Y. Selin and J. L. Johnson, J. Dent. Res. 60[Special Issue
A]:415, abstr. no. 420, 1981). This suggests that antigenic
differences may be possible within the F. nucleatum strains.
Other investigators have reported cross-reactivity for poly-
clonal antiserum produced in rabbits (6). These workers
showed that rabbit antisera to F. nucleatum ATCC 10953
and ATCC 23726 reacted with both F. nucleatum strains but
showed no cross-reactivity with F. mortiferum or F. varium.
In a later study, Falkler et al. (7) produced rabbit anti-F.
nucleatum ATCC 10953 serum which cross-reacted with
three strains ofF. nucleatum (ATCC 10953, ATCC 4355, and
ATCC 10195). Stauffer et al. (29) demonstrated that another
rabbit antiserum against fusobacteria detected strain speci-
ficity, specificity for groups within subspecies, occasionally
specificity among strains representing subspecies. They sug-
gested that a study of additional strains might demonstrate
the existence of distinct antigenic groups within the species.
Even though there is heterogeneity among the strains of F.
nucleatum, it has been reported that the major antigenic
determinants of the different isolates are similar (32). Indeed,
in a report of a DNA-DNA hybridization study of 16 strains
of F. nucleatum (24), it was concluded that F. nucleatum
comprises a heterogeneous group of microorganisms closely
related to Fusobacterium periodonticum and Fusobacterium
simiae but unrelated to other Fusobacterium species tested.
This study did not include F. russii. MAbs have been
generated that cross-react with F. nucleatum strains and F.
periodonticum, showing a close relationship between these
species (3).
In the present report, species-specific, strain-specific, and
cross-reactive MAbs are described. It would be of interest to
define a pattern of antigenic relationship, using these MAbs,
within a larger number of F. nucleatum strains. MAbs then
could be used as diagnostic reagents in the identification of
F. nucleatum isolates. Species-specific antisera have been
used in an indirect immunofluorescence assay for the rapid
detection and identification of Fusobacterium species in
clinical specimens (29). Similarly, the MAbs described in the
present report have been used to detect F. nucleatum in
dental plaque. Further work will be necessary to determine
whether such an approach has clinical applications.
In the present study, whole "aerobically" killed bacteria
were used as immunogens, and in the screening ELISA,
glutaraldehyde-fixed whole bacteria were used. The reactiv-
ity with whole bacteria in absorption experiments showed
that the antigenic character was unaltered by these treat-
ments. Nevertheless, it has been reported that Formalin
fixation denatures the antigens and that these antigens may
not be detected in an ELISA (2).
The relationship of the MAbs to the epitopes on F.
nucleatum 263 was determined by the additive binding assay
(8). The results are expressed as percentages, with lower
percentages suggesting epitope sharing. The percentages
obtained therefore indicate whether the MAbs could be
sharing the same epitope or whether different epitopes may
be involved; they may also indicate the degree of overlap
between epitopes. There was an indication that MAbs 4BD6
and 4AA1 (4%) compete for the same epitope; similarly,
4BD6 and 6CD2 (4%) may share an epitope. The same
antigenic determinant could be detected by the MAbs react-
ing with different antigenic sites on the antigen which may be
partially shared by the MAbs or could be epitopes at some
distance from one another. The range of percentages shown
in Table 3 suggests the different degrees of overlap that may
exist between the epitopes detected. Some variability in the
results was noted in the additive binding assay, and it was
thought that a better approach to the study of the relation-
ship of MAbs to epitope binding would be a competitive
inhibition assay with labeled and unlabeled MAbs. In such
an assay, horseradish peroxidase-conjugated MAb 4BA4
was shown not to be inhibited by any unlabeled MAb other
than 4BA4. Knowing whether MAbs react with the same or
different epitopes helps in developing a better set of reagents
for use in diagnosis and in immunological probes.
The nature of the antigens recognized by the MAbs is
unknown and subject to current investigations. The MAbs
may react with protein, lipopolysaccharide, or lipid compo-
nents of the bacterial cell wall. The main purpose of this
study was the production of the MAbs to enable the isolation
and purification of bacterial antigens which could then be
used to elicit an immunological response of known speci-
ficity.
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